BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23238783)

  • 1. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
    Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
    Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
    Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
    Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
    Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
    Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
    Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
    Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
    Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
    Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.
    Lamba V; Lamba J; Yasuda K; Strom S; Davila J; Hancock ML; Fackenthal JD; Rogan PK; Ring B; Wrighton SA; Schuetz EG
    J Pharmacol Exp Ther; 2003 Dec; 307(3):906-22. PubMed ID: 14551287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
    Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.
    Benowitz NL; Zhu AZ; Tyndale RF; Dempsey D; Jacob P
    Pharmacogenet Genomics; 2013 Mar; 23(3):135-41. PubMed ID: 23344581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
    Kharasch ED; Mitchell D; Coles R
    J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
    Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
    Trials; 2011 Jan; 12():22. PubMed ID: 21266057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.
    Qin WJ; Zhang W; Liu ZQ; Chen XP; Tan ZR; Hu DL; Wang D; Fan L; Zhou HH
    Br J Clin Pharmacol; 2012 Dec; 74(6):999-1004. PubMed ID: 22519658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.
    Chung JY; Cho JY; Lim HS; Kim JR; Yu KS; Lim KS; Shin SG; Jang IJ
    Drug Metab Dispos; 2011 Jan; 39(1):92-7. PubMed ID: 20876786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
    Kharasch ED; Lenze EJ
    Drug Metab Dispos; 2024 Apr; 52(5):455-466. PubMed ID: 38467432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
    Fan L; Wang JC; Jiang F; Tan ZR; Chen Y; Li Q; Zhang W; Wang G; Lei HP; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Apr; 65(4):403-9. PubMed ID: 19066872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
    Kim H; Bae SK; Park SJ; Shim EJ; Kim HS; Shon JH; Liu KH; Shin JG
    Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
    Kharasch ED; Mitchell D; Coles R; Blanco R
    Antimicrob Agents Chemother; 2008 May; 52(5):1663-9. PubMed ID: 18285471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C; Ogburn ET; Guo Y; Desta Z
    Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.